Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.67 |
| ▸ | EGFR | P00533 | 14/20 | 0.67 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18011052 | 0.91 | EGFR (0.66) | ERBB2EGFRAAK1 | |
| SCHEMBL14017663 | 0.87 | AAK1 (0.74) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL6099658 | 0.87 | EGFR (0.61) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL18011043 | 0.84 | AAK1 (0.80) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL4562683 | 0.81 | EGFR (0.56) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1220319 | 0.81 | ERBB2 (0.75) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL18011049 | 0.80 | AAK1 (0.56) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL6100942 | 0.80 | EGFR (0.66) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1219763 | 0.80 | ERBB2 (1.00) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1220220 | 0.80 | ERBB2 (0.77) | ERBB2EGFRAAK1LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ERBB2 32/4885EGFR 408/4885AAK1 204/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | ERBB2 162/4885EGFR 1009/4885AAK1 120/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ERBB2 32/4885EGFR 408/4885AAK1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.